WASHINGTON, July 23 (Reuters) - The U.S. Justice Department
said on Thursday that it would not challenge on antitrust
grounds pharmaceutical companies that seek to share information
about how best to manufacture a coronavirus treatment related to
monoclonal antibodies.
The department said in a business review letter that it
would allow Eli Lilly and Co, AbCellera Biologics, Amgen
Inc, AstraZeneca, Genentech
and GlaxoSmithKline to share information about producing
the antibody treatments needed to treat COVID-19.
(Reporting by Diane Bartz; Editing by Leslie Adler)